These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8916707)

  • 1. Cost effectiveness of lowering cholesterol. Study greatly underestimates the cost effectiveness of statin treatment.
    McMurray JJ; Morrison CE
    BMJ; 1996 Nov; 313(7065):1142; author reply 1144. PubMed ID: 8916707
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost effectiveness of lowering cholesterol. Statin treatment should be started early.
    Masters P; Shetty A
    BMJ; 1996 Nov; 313(7065):1143; author reply 1144. PubMed ID: 8916710
    [No Abstract]   [Full Text] [Related]  

  • 3. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis.
    Cobos A; Jovell AJ; García-Altés A; García-Closas R; Serra-Majem L
    Clin Ther; 1999 Nov; 21(11):1924-36. PubMed ID: 10890264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Limitations of interventions against hypercholesterolemia].
    Ripoll MA
    Aten Primaria; 1996 Mar; 17(4):305-6. PubMed ID: 8679872
    [No Abstract]   [Full Text] [Related]  

  • 6. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. Scandinavian Simvastatin Survival Study Group.
    Johannesson M; Jönsson B; Kjekshus J; Olsson AG; Pedersen TR; Wedel H
    N Engl J Med; 1997 Jan; 336(5):332-6. PubMed ID: 9011785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Lowering LDL cholesterol with Simvastatin. Also, economically reasonable!].
    Internist (Berl); 1995 Aug; 36(8 Suppl):1-4. PubMed ID: 9131077
    [No Abstract]   [Full Text] [Related]  

  • 8. [Cost-effectiveness of lowering of blood cholesterol using simvastatin and cholestyramine].
    Martens LL; Rutten FF; Kuijpens JL; Winter J
    Ned Tijdschr Geneeskd; 1991 Apr; 135(15):655-9. PubMed ID: 1903849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of simvastatin versus cholestyramine: results for Sweden.
    Hjalte K; Lindgren B; Persson U
    Pharmacoeconomics; 1992 Mar; 1(3):213-6. PubMed ID: 10147032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Data on cholesterol level screening of patients with ischemic heart disease in the light of the Scandinavian Simvastatin Survival Study].
    Márk L; Kondacs A; Hanyecz V; Simondán G
    Orv Hetil; 1997 Jun; 138(26):1679-82. PubMed ID: 9289681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of drug therapy for hypercholesterolaemia: a review of the literature.
    Thompson D; Oster G
    Pharmacoeconomics; 1992 Jul; 2(1):34-42. PubMed ID: 10146977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmaco-economic assessment of the HMG-CoA reductase inhibitors.
    Smart AJ; Walters L
    S Afr Med J; 1994 Dec; 84(12):834-7. PubMed ID: 7570232
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Scandinavian simvastatin study (4S).
    Grodos D; Tonglet R
    Lancet; 1994 Dec 24-31; 344(8939-8940):1768. PubMed ID: 7997017
    [No Abstract]   [Full Text] [Related]  

  • 14. Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease.
    Chrisp P; Lewis NJ; Milne RJ
    Pharmacoeconomics; 1992 Feb; 1(2):124-45. PubMed ID: 10146941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system].
    Araujo DV; Ribeiro de Souza CP; Bahia LR; Rey HC; Dos Santos Junior B; Tura BR; Berwanger O; Buehler AM; Silva MT
    Value Health; 2011; 14(5 Suppl 1):S29-32. PubMed ID: 21839894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cost of reaching National Cholesterol Education Program (NCEP) goals in hypercholesterolaemic patients. A comparison of atorvastatin, simvastatin, lovastatin and fluvastatin.
    Koren MJ; Smith DG; Hunninghake DB; Davidson MH; McKenney JM; Weiss SR; Schrott HG; Henley RW; Tresh P; McLain RW; Bakker-Arkema RG; Black DM
    Pharmacoeconomics; 1998 Jul; 14(1):59-70. PubMed ID: 10182195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of lowering cholesterol. Full treatment of the costs and benefits is needed.
    Wierzbicki AS; Reynolds TM
    BMJ; 1996 Nov; 313(7065):1143; author reply 1144. PubMed ID: 8916709
    [No Abstract]   [Full Text] [Related]  

  • 18. Simvastatin. A reappraisal of its cost effectiveness in dyslipidaemia and coronary heart disease.
    Goa KL; Barradell LB; McTavish D
    Pharmacoeconomics; 1997 Jan; 11(1):89-110. PubMed ID: 10172918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative effectiveness of lipid-lowering treatments to reduce cardiovascular disease.
    Suh DC; Griggs SK; Henderson ER; Lee SM; Park T
    Expert Rev Pharmacoecon Outcomes Res; 2018 Feb; 18(1):51-69. PubMed ID: 29148854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of diagnostic cluster methodology for therapeutic costing and drug surveillance of HMG-CoA reductase-inhibitor therapy.
    Bottorff MB; Yenkowsky JP; Cave DG
    Clin Ther; 1999 Jan; 21(1):218-35. PubMed ID: 10090437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.